IBB Ventures funds Charité, MDC spinout MyoPax in first B# Plus pre — seed round
MyoPax secured B# Plus pre-seed funding from IBB Beteiligungsgesellschaft mbH’s IBB Ventures, marking the first deal under the new variant. The Berlin biotech develops a platform combining regenerative muscle stem cell therapy with CRISPR/Cas gene repair for genetic muscle-wasting diseases. Funding supports scale-up of